Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 10, 2011, Pages 2141-2149

  McBride, Stephan ^a   Sarsour, Khaled ^b   White, Leigh Ann ^a   Nelson, David R ^b   Chawla, Anita J ^a   Johnston, Joseph A ^b  

^a ANALYSIS GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Biologics; Disease modifying treatment; Healthcare costs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PRESCRIPTION DRUG; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHRALGIA; ARTICLE; BIOLOGICAL THERAPY; COMORBIDITY; DATA BASE; DISEASE SEVERITY; DRUG COST; DRUG USE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SERVICE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053540921     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101195     Document Type: Article

References (24)

1. Weyand CM, Goronzy JJ. Pathogenesis of rheumatoid arthritis. Med Clin North Am 1997;81:29-55. (Pubitemid 27043794)
2. Helmick CG, Felson DT, Lawrence RC. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States - Part I. Arthritis Rheum 2008;58:15-25.
3. Saag KG, Teng GG, Patkar NM, Anuntivo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
4. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
5. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13.
6. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84.
7. Gomez-Reino JJ, Carmona L, and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
8. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;4:243-52.
9. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8 Suppl:849-60.
10. Wu E, Chen L, Birnbaum HG, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749-59. (Pubitemid 47300371)
11. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-62. (Pubitemid 37280602)
12. Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588-96. (Pubitemid 30415312)
13. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996 Mar;44:47-51. (Pubitemid 26094647)
14. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 2003;46:1075-9.
15. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3:1-154.
16. Duan N, Manning WG Jr, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983;1:115-26.
17. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998;17:247-81. (Pubitemid 28300216)
18. Madden D. Sample selection versus two-part models revisited: the case of female smoking and drinking. J Health Econ 2008;27:300-7.
19. Hogan JW, Lancaster T. Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies. Stat Methods Med Res 2004;13:17-48. (Pubitemid 38094365)
20. Robins JM. Association, causation, and marginal structural models. Synthese 1999;121:151-79.
21. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. (Pubitemid 30660034)
22. Fewell Z, Hernán MA, Wolfe F, Tilling K, Choie H, Sterne JAC. Controlling for time-dependent confounding using marginal structural models. Stata J 2004;4:402-20.
23. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
24. Grijalva CG, Chung CP, Stein CM, Mitchel EF Jr, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology 2008;47:1061-4. (Pubitemid 351865934)